 Following myocardial infarct, cellular therapy is a potential approach to repopulate the injured myocardium, to treat heart failure and restore cardiac function. The purpose of this study is to assess the safety, feasibility and efficacy of intramyocardial delivery of selected autologous CD133 bone marrow stem cells at time of coronary artery bypass grafting in patients with chronic ischemic cardiomyopathy. 